The effect of chronic treatment with a non-selective beta-adrenoceptor antagonist on the enteroinsular axis and intermediary metabolites.
In a single-blind randomized placebo-controlled cross-over study in hypertensive patients we have examined the effects of treatment with the non-selective beta-adrenoceptor antagonist nadolol on the responses of glucose, intermediary metabolites and the hormones of the enteroinsular axis to the ingestion of a mixed meal. During treatment with nadolol the plasma insulin concentration 30 min after ingesting the meal was significantly lower than on placebo and the plasma glucose rose more slowly. Plasma concentrations of GIP tended to be higher during nadolol than placebo treatment. No significant effects of treatment with nadolol were noted on pancreatic glucagon or intermediary metabolites.
D020155:3-Hydroxybutyric Acid; D000328:Adult; D000368:Aged; D000409:Alanine / Q000097:blood; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005934:Glucagon / Q000097:blood; D006801:Humans; D006885:Hydroxybutyrates / Q000097:blood; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D007700:Kinetics; D007773:Lactates / Q000097:blood; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D011412:Propanolamines / Q000627:therapeutic use*; D011773:Pyruvates / Q000097:blood
D000959:Antihypertensive Agents; D001786:Blood Glucose; D006885:Hydroxybutyrates; D007328:Insulin; D007773:Lactates; D011412:Propanolamines; D011773:Pyruvates; D009248:Nadolol; D005749:Gastric Inhibitory Polypeptide; D005934:Glucagon; D000409:Alanine; D020155:3-Hydroxybutyric Acid